Causes of Multiple Cherry Angiomas
Multiple cherry angiomas are primarily age-related benign vascular proliferations, but when appearing suddenly or in large numbers (>10), they warrant clinical evaluation for potential associations with toxic exposures, certain medications (particularly tamsulosin), malignancies (especially melanoma and lymphoproliferative disorders), and immunosuppression.
Primary Cause: Aging
The most common cause of cherry angiomas is simply advancing age. These lesions become increasingly prevalent in the general population with aging, representing the most common vascular tumors of the skin 1, 2. The median number increases progressively with age, and this association has been recognized for decades 3.
Secondary Causes Requiring Clinical Attention
Toxic Exposures
Environmental toxins can trigger eruptive cherry angiomas. The most well-documented case involves acute exposure to 2-butoxyethanol (a glycol ether solvent), where workers developed multiple new cherry angiomas beginning 4 months after a single acute exposure, with new lesions continuing to appear for 5 years afterward 4. This demonstrates that chemical exposures can induce persistent angioma formation.
Medication Associations
Tamsulosin use is an independent risk factor for developing multiple cherry angiomas (OR = 3.475, p = 0.009) 5. Conversely, clopidogrel appears protective against cherry angioma development (OR = 0.281, p = 0.028) 5.
Malignancy Associations
The relationship between cherry angiomas and cancer requires careful attention:
Melanoma: Multiple cherry angiomas (>10) show a strong association with malignant melanoma, with a strength of association comparable to having >2 atypical melanocytic nevi, particularly in patients younger than 70 years 6. This association was confirmed across 1,190 subjects in a cross-sectional study.
Breast cancer: Women with breast cancer demonstrate asymmetric distribution of cherry angiomas, with significantly more lesions on the affected breast side compared to the contralateral side (p <0.0001) 7.
Lymphoproliferative disorders: Eruptive cherry hemangiomatosis (sudden onset of multiple lesions) can herald multicentric Castleman disease, likely mediated by elevated interleukin-6 and vascular endothelial growth factor 8.
Other Associations
Benign prostatic hyperplasia showed association in bivariate analysis but not in multivariate analysis 5. Immunosuppression has been linked to cherry angioma development 1, 2.
Clinical Algorithm for Evaluation
When encountering a patient with multiple cherry angiomas:
Determine if eruptive (sudden onset) or gradual:
- Eruptive presentation demands immediate workup
- Gradual accumulation with age is typically benign
Count the lesions:
10 cherry angiomas warrants closer evaluation
- Document distribution pattern (symmetric vs. asymmetric)
Assess for red flags:
- Systemic symptoms (fever, weight loss, lymphadenopathy)
- Personal history of melanoma or other malignancies
- Recent toxic exposures
- Current medications (especially tamsulosin)
- Age <50 with numerous lesions
Risk-stratified follow-up:
- Eruptive presentation with systemic symptoms: Evaluate for lymphoproliferative disorders (CBC, comprehensive metabolic panel, imaging for lymphadenopathy) 8
- History of melanoma or >10 angiomas: Enhanced melanoma surveillance 6
- Asymmetric distribution in women: Consider breast examination and age-appropriate screening 7
- Recent chemical exposure: Document exposure, monitor for new lesions, reassure regarding lack of serious systemic toxicity 4
Important Caveats
- The temporal relationship between cherry angiomas and malignancy remains unclear—whether angiomas develop before, concurrent with, or after cancer diagnosis 7
- While associations exist, cherry angiomas themselves are benign and do not require treatment unless for cosmetic concerns
- Male sex, Caucasian ancestry (non-British/Irish), fair skin, and green/hazel eyes are demographic risk factors for having more cherry angiomas 3
- The pathophysiologic mechanism likely involves vascular endothelial growth factor dysregulation in cases associated with systemic disease 8